Cel Sci (CVM) EBIT Margin (2010 - 2017)
Cel Sci (CVM) reported EBIT Margin of -27366.26% for fiscal Q3 2017 (quarter ended Jun 30, 2017), down 22822.20 percentage points from -4544.06% a year earlier.
Cel Sci (CVM) EBIT Margin (2010 - 2017) Analysis & Trends
Over the twelve months ended Jun 30, 2017, Cel Sci's EBIT Margin came in at -9481.25%.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | 32.97% |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 20.57% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 34.95% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -133.21% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 28.37% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 37.40% |
| 10 | Cel Sci | 3.22 Mn | -22.43 Mn | - | - |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2017 | -27,366.26% |
| Jun 30, 2016 | -4,544.06% |
| Jun 30, 2011 | -6,260.41% |
| Jun 30, 2010 | -10,984.01% |
Cel Sci EBIT Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebit-margin&ticker=CVM&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebit-margin", "ticker": "CVM", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebit-margin&ticker=CVM&period=max&api_key=YOUR_API_KEY");
const data = await res.json();